Yang, L., Qiu, Q., Wang, J., Wen, Y., Li, H., Liang, R., . . . Niu, T. (2025). Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma. Nature Publishing Group.
Chicago Style (17th ed.) CitationYang, Linyu, et al. Preclinical and First-in-human of Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Relapsed/refractory Multiple Myeloma and Lymphoma. Nature Publishing Group, 2025.
MLA (9th ed.) CitationYang, Linyu, et al. Preclinical and First-in-human of Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Relapsed/refractory Multiple Myeloma and Lymphoma. Nature Publishing Group, 2025.
Warning: These citations may not always be 100% accurate.